Livforsakringsbolaget Skandia, Omsesidigt Moderna, Inc. Transaction History

Livforsakringsbolaget Skandia, Omsesidigt

$1.22 Billion
Q2 2024

A detailed history of Livforsakringsbolaget Skandia, Omsesidigt transactions in Moderna, Inc. stock. As of the latest transaction made, Livforsakringsbolaget Skandia, Omsesidigt holds 733 shares of MRNA stock, worth $48,194. This represents 0.01% of its overall portfolio holdings.

Number of Shares

733

Previous 733 -0.0%

Holding current value

$48,194

Previous $78,000 11.54%

% of portfolio

0.01%

Previous 0.01%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 31, 2024	SELL	$69.51 - $104.43 $268,795 - $403,830	-3,867 Reduced 84.07%	733 $72,000
Q2 2023 Jul 06, 2023	SELL	$118.5 - $160.53 $47,400 - $64,212	-400 Reduced 8.0%	4,600 $558,000
Q3 2022 Nov 14, 2022	SELL	$118.07 - $194.18 $283,368 - $466,032	-2,400 Reduced 32.43%	5,000 $591,000
Q2 2022 Aug 16, 2022	SELL	$117.13 - $176.59 $93,704 - $141,272	-800 Reduced 9.76%	7,400 $1.06 Million
Q4 2021 Feb 14, 2022	SELL	$225.82 - $368.51 $293,566 - $479,063	-1,300 Reduced 13.68%	8,200 $2.08 Million
Q3 2021 Oct 28, 2021	SELL	$221.9 - $484.47 $177,520 - $387,576	-800 Reduced 7.77%	9,500 $3.66 Million
Q2 2021 Jul 13, 2021	BUY	$129.91 - $234.98 $467,676 - $845,928	3,600 Added 53.73%	10,300 $2.42 Million
Q1 2021 May 07, 2021	BUY	$109.18 - $185.98 $272,950 - $464,950	2,500 Added 59.52%	6,700 $877,000
Q4 2020 Mar 02, 2021	BUY	$65.74 - $169.86 $138,054 - $356,706	2,100 Added 100.0%	4,200 $439,000
Q3 2020 Nov 09, 2020	SELL	$54.34 - $94.85 $103,246 - $180,215	-1,900 Reduced 47.5%	2,100 $149,000
Q2 2020 Jul 08, 2020	BUY	$29.67 - $80.0 $118,680 - $320,000	4,000 New	4,000 $257,000

Others Institutions Holding MRNA

# of Institutions

1,113

Shares Held

241M

Call Options Held

9.26M

Put Options Held

12.1M

View Full List

About Moderna, Inc.

Ticker MRNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 391,200,000
Market Cap $25.7B
Description
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, resp...

More about MRNA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Livforsakringsbolaget Skandia, Omsesidigt, based on Form 13F filings with the SEC.

News

Stay updated on Livforsakringsbolaget Skandia, Omsesidigt with notifications on news.

Account

Livforsakringsbolaget Skandia, Omsesidigt Moderna, Inc. Transaction History